Douglas M. Fambrough III
Net Worth

Last updated:

What is Douglas M. Fambrough III net worth?

The estimated net worth of Dr. Douglas M. Fambrough III is at least $16,606,606 as of 15 Dec 2021. He owns shares worth $1,649,728 as insider, has earned $3,683,238 from insider trading and has received compensation worth at least $11,273,640 in Dicerna Pharmaceuticals, Inc..

What is the salary of Douglas M. Fambrough III?

Dr. Douglas M. Fambrough III salary is $939,470 per year as Co-Founder, Chief Executive Officer, Pres & Director in Dicerna Pharmaceuticals, Inc..

How old is Douglas M. Fambrough III?

Dr. Douglas M. Fambrough III is 56 years old, born in 1969.

What stocks does Douglas M. Fambrough III currently own?

As insider, Dr. Douglas M. Fambrough III owns shares in one company:

Company Title Shares Price per share Total value
Dicerna Pharmaceuticals, Inc. (DRNA) Co-Founder, Chief Executive Officer, Pres & Director 43,164 $38.22 $1,649,728

What does Dicerna Pharmaceuticals, Inc. do?

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

DRNA logo
DRNA
Dicerna Pharmaceuticals, Inc.
$38.22

Douglas M. Fambrough III insider trading

Dicerna Pharmaceuticals, Inc.

Dr. Douglas M. Fambrough III has made 2 insider trades between 2013-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 179,865 units of DRNA stock on 10 Dec 2021. As of 15 Dec 2021 he still owns at least 43,164 units of DRNA stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 13,750 N/A N/A
Option
Restricted Stock Units 13,750 N/A N/A
Option
Employee Stock Option (Right to Buy) 179,865 $3.2 $574,669
Option
Common Stock 179,865 $3.2 $574,669
Purchase
Common Stock 5,000 $22.1 $110,480
Option
Common Stock 19,950 N/A N/A
Option
Restricted Stock Units 19,950 N/A N/A
Purchase
Common Stock 10,000 $18.06 $180,600
Option
Common Stock 80,000 $3.42 $273,600
Sale
Common Stock 80,000 $26.46 $2,116,880
Option
Employee Stock Option (Right to Buy) 80,000 $3.42 $273,600
Sale
Common Stock 59,021 $26.54 $1,566,358
Purchase
Common Stock 16,500 $3.63 $59,895
Purchase
Common Stock 16,600 $3.78 $62,748
Option
Common Stock 2,500 $3.42 $8,550
Option
Employee Stock Option (Right to Buy) 1,050 $3.42 $3,591
Purchase
Common Stock 5,000 $15 $75,000
Option
Common Stock 9,300 $3.42 $31,806
Option
Employee Stock Option (right to buy) 9,300 $1.71 $15,903

Dicerna Pharmaceuticals key executives

Dicerna Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: